Molecular Analysis and Results - DNA
互联网
- The tumor DNA is labeled with FITC-dUTP and normal DNA with TexasRed-dUTP prior to hybridization.
- Three images of the hybridization, representing both fluorescent labels as well as DNA counterstain (DAPI), are acquired using epifluorescence microscopy and a CCD camera interfaced to a computer.
- Subsequently, an image analysis software program is used to calculate green-red fluorescence intensity ratio profiles along all chromosomes.
- Regions of the genome that are either gained or lost in the tumor are indicated by the differences between binding of the two labeled DNAs as evidenced by the fluorescence intensity ratio profiles.
Thus, in a single hybridization it is possible to screen all chromosomal sites that may contain genes that are either deleted or amplified in cancer.
Sensitivity
The sensitivity of CGH in detecting gains and losses of DNA sequences is approximately 2-20 Mb. For example, a 10-fold amplification of a 200 kb region should be detectable under optimal hybridization conditions. Early CGH experiments were done using DNA isolated from freshly frozen tumor tissues. However, it has now been shown that DNA extracted from formalin-fixed paraffin-embedded archival tissue blocks can be used as well. Prior to CGH hybridization, DNA can be universally amplified using degenerate oligonucleotide-primed PCR (DOP-PCR), which allows the analysis of, for example, microdissected tumor samples. The latter technique is, however, more difficult and less reliable than CGH without PCR pre-amplification step.
Applications of CGH
CGH has been used to detect genetic aberrations in a variety of malignancies:
- It has already revealed a complex genetic nature of cancer and indicated several novel chromosomal regions that are frequently altered in tumors.
- Several CGH studies on prostate cancer have been published, e.g., loss of 6q, 8p, 13q, and 16q, as well as gains of 7p, 7q, 8q and Xq, have been found to be common alterations in prostate cancer.
- CGH findings led also to the discovery of androgen receptor (AR) gene amplification in hormone-refractory recurrent prostate carcinomas.
